Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Jul 15 2016

• By Sue Sutter

Related Content

Celltrion's Biosimilar Gets FDA Panel Nod Despite Extrapolation Concerns

Feb 10 2016

Inflectra's Label Won't Depend On Continuing Study In IBD

Feb 10 2016

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

Apr 06 2016

Inflectra Reviewers

Jul 15 2016

Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes

Jul 15 2016

Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Jul 15 2016

With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans

Jul 15 2016

Related Companies

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Amgen, Inc.

Additional Topics

United States Biosimilars Approvals Drug Review BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window